Campath-1H: Pivotal Phase II

Researchers presented data from 92 patients in the U.S. and Europe refractory to fludarabine who received a 30 mg Campath infusion three times a week for 4-12 weeks in a pivotal Phase II study. The overall response rate was 33 percent, with 2 complete responses, 29 partial responses and 55 patients with stable disease. After a median follow-up of 9 months, 26 patients had died, 6 of whom had infections possibly related to Campath. The researchers concluded that the product is effective and relatively safe in fludarabine-refractory patients. The data were presented at the European Haematology Association meeting in Barcelona. ...